EPI-326: A Clinical Stage Mutation-Independent, Normal Tissue-Sparing EGFR Bispecific Antibody that Degrades EGFR for the Treatment of EGFR-Driven Solid Tumors
2:45 pm - Wednesday 28th October 2026
- Highlighting new preclinical data supporting monotherapy and combination opportunities for EPI-326, which was designed to degrade all forms of EGFR in a tumor-selective manner that spares healthy tissue
- First-in-human study of EPI-326, our lead tumor-selective EGFR degrader, is currently enrolling patients in a global phase 1 study in patients with NSCLC and HNSCC with potential to expand to CRC
- EpiBiologics is building a pipeline of EpiTAC therapies for oncology, including EpiTAC degrader ADCs, and autoimmunity
